|
WO2020154315A1
|
|
Methods for treating schizophrenia
|
|
WO2020077235A1
|
|
Buprenorphine to treat respiratory depression
|
|
WO2019241709A1
|
|
Syringe system
|
|
US2019015415A1
|
|
Methods for treating schizophrenia
|
|
US2019380909A1
|
|
Syringe system
|
|
US2018360821A1
|
|
Methods to treat opioid use disorder
|
|
AU2018283724A1
|
|
Methods to treat opioid use disorder
|
|
CA2995923A1
|
|
Methods to treat opioid use disorder
|
|
GB201716346D0
|
|
Methods for detecting naloxone degradation products
|
|
WO2017153933A1
|
|
Abuse-resistant pharmaceutical formulations
|
|
CA3003650A1
|
|
Quantification of drugs in biological samples
|
|
WO2017059106A1
|
|
Psychiatric treatment for patients with gene polymorphisms
|
|
CA2992820A1
|
|
Dopamine d3 receptor antagonists having a bicyclo moiety
|
|
AU2015341490A1
|
|
Buprenorphine dosing regimens
|
|
KR20170090422A
|
|
Dopamine d3 receptor antagonist compounds
|
|
GB201518125D0
|
|
Dopamine D3 receptor antagonist having a bicyclo moiety
|
|
GB201518124D0
|
|
Dopamine D3 receptor antagonists having a morpholine moiety
|
|
GB201513871D0
|
|
Bicyclo dopamine D3 receptor antagonists
|
|
EP3082816A1
|
|
Intranasal naloxone compositions and methods of making and using same
|
|
AU2011203283A1
|
|
Microbial N- and O-demethylation of a thebaine derivative
|
